Brian Rabinovich

EMD Serono, Inc. (United States)

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

EMD Serono, Inc. (United States)

Research Subjects

Research Interests

Brian Rabinovich has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

Amit M. Deshpande
Mythic Therapeutics Inc., Waltham, Massachusetts
33 shared publications
Chunxiao Xu
EMD Serono Res Ctr, Res Unit Oncol, 45 Middlesex Turnpike, Billerica, MA 01821 USA
33 shared publications
Laura Helming
Research Unit Oncology, EMD Serono, EMD Serono Research & Development Institute
33 shared publications
Lindsay Webb
Research Unit Oncology, EMD Serono, Billerica, Massachusetts
33 shared publications
Marat Alimzhanov
Research Unit Oncology, EMD Serono, Billerica, Massachusetts
33 shared publications
Maria Soloviev
Discovery and Development Technologies, EMD Serono, Billerica, Massachusetts
33 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
M9567 mAb2 TM structure and molecules used for primary research
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S1 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
M9567 mAb2 TM structure and molecules used for primary research
Open Access
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S13 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
Tumor-targeted immune activation does not result in increased liver inflammation
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S13 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
Tumor-targeted immune activation does not result in increased liver inflammation
Open Access
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
M9657 is not appreciably internalized in MSLN+ cells
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S2 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
M9657 is not appreciably internalized in MSLN+ cells
Open Access
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S10 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
FS122m generates dose-dependent antitumor efficacy and long-term tumor antigen-specific immune protection.
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S10 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
FS122m generates dose-dependent antitumor efficacy and long-term tumor antigen-specific immune protection.
Open Access
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S7 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
FS122m characterization on cellular binding, in vitro agonism and in vivo distribution
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S7 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
FS122m characterization on cellular binding, in vitro agonism and in vivo distribution
Open Access
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S8 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
FS122m surrogate and M9657 chimeric antibodies display significant antitumor efficacy in syngeneic models
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S8 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
FS122m surrogate and M9657 chimeric antibodies display significant antitumor efficacy in syngeneic models
Open Access
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S8 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
FS122m surrogate and M9657 chimeric antibodies display significant antitumor efficacy in syngeneic models
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S8 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
FS122m surrogate and M9657 chimeric antibodies display significant antitumor efficacy in syngeneic models
Open Access
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
M9657 is not appreciably internalized in MSLN+ cells
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S2 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
M9657 is not appreciably internalized in MSLN+ cells
Open Access
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S11 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
FS122m increases infiltration of CD8+ T cells but not other immune subsets in the TME and spleen of the CT26-KSA tumor model
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S11 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
FS122m increases infiltration of CD8+ T cells but not other immune subsets in the TME and spleen of the CT26-KSA tumor model
Open Access
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S9 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
MuMSLN was depleted in the EMT‑6‑ MSLN‑del cell line
Website
Google Scholar
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S9 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
by Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, et al.
MuMSLN was depleted in the EMT‑6‑ MSLN‑del cell line

Show all